维普中文期刊产品整合服务
51篇 您的检索式:作者名="Tari L"
    题名 作者 年代 出处 被引量
1Plant aromatic L-amino acid decarboxylases:evolution,biochemistry,regulation,and metabolic engineering applications显示文摘FACCHINI P J HUBER ALLANACH K L TARI L W 2000Phytochemistry2000,54,2:1
2Discovering drug-drug interactions:a text-mining and reasoning approach basedon properties of drug metabolism显示文摘Tari L Anwar S Liang S Cai J Baral C 2010Bioinformatics2010,26,18:1
3Discovering drug–drug interactions:a text-mining and reasoning approach based on properties of drug metabolism显示文摘Tari L Anwar S Liang S 2010Bioinformatics2010,26,18:1
4Discovering drug-druginteractions:a text-mining and reasoning approach basedon properties of drug metabolism显示文摘Tari L Anwar S Liang S 2010Bioinformatics2010,26,18:1
5Reinforcement sensitivity theory and occupational health:BAS and BIS on the job显示文摘VAN D L TARIS D BECKER T W 2007Personality and Individual Differences2007,42,6:1
6The Role of the Synergistic Phosphate Anion in Iron Transport by the Periplasmic Iron-binding Protein from Haemophilus Influenzae显示文摘Khan A G Shouldice S R Tari L W 0,,:1
7Fuzzy c-means clustering with prior biological knowledge显示文摘Tari L Baral C Kim S 2009Journal of Biomedical Informatics2009,42,1:1
8Fuzzy c-means clustering with prior biological knowledge显示文摘Tari L Baral C Kim S 2009Journal of Biomedical Informatics2009,42,1:1
9Fuzzy c-means clustering with prior biological knowledge显示文摘Tari L Baral C Kim S 2009Journal of Biomedical Informafics2009,42,1:1
10Discovering drugdrug interactions: a text-mining and reasoning approach based on properties of drug metabolism显示文摘Tari L Anwar S Liang S Cai J Baral C 2010Bioinformatics2010,26,18:1
11早期乳腺癌最佳辅助化疗方案与人类表皮生长因子受体2阳性乳腺癌辅助靶向治疗选择:依据 ASCO 对 CCO临床实践指南的改编显示文摘目的研究加拿大安大略癌症治疗中心(CCO)关于早期乳腺癌最佳辅助化疗方案,包括人类表皮生长因子受体2(HER2)阳性乳腺癌辅助靶向治疗方案,并对其进行改编。方法按照美国临床肿瘤协会(ASCO)对其他组织临床实践指南改编的策略和程序,对CCO临床实践指南的严谨性与内容适用性进行回顾。结果基于对CCO临床实践指南内容的回顾,ASCO小组认为,CCO临床实践指南在整体上清晰全面,以最确切的科学证据为基础,为患者提供可接受的治疗选项。推荐关于辅助化疗方案的决定,应考虑到基线复发风险、毒性、利益可能性和宿主因素(如合并症)。对于高风险HER2阴性的身体状况良好的人群,蒽环类和紫杉烷治疗方案是标准治疗方案。4个周期的多西他赛和环磷酰胺治疗方案是可接受的非蒽环类治疗方案。对于高风险HER2阳性患者,推荐蒽环类与紫杉烷序贯疗法联合曲妥单抗或多西他赛、卡铂、曲妥单抗进行6个周期的治疗。对于低风险、非淋巴结转移、HER2阳性人群,推荐每周一次的紫杉醇和曲妥单抗连续进行12个周期的替代治疗。曲妥单抗应持续使用1年。不应采用铂复合盐对三阴性人群进行常规的辅助管理,除非出现有效的生存数据加以支持。Neelima Denduluri Mark R Somerfield Andrea Eisen Jamie N Holloway Arti Hurria Tari A King Gary H Lyman Ann H Partridge Melinda L Telli Maureen E Trudeau Antonio C Wolff 本刊编辑部 2016中国全科医学2016,19,18:1
12Fuzzy C-means clustering with prior biological knowledge显示文摘Tari L Baral C Kim S 2009Journal of Bio- medical Informatics2009,42,1:1
13Structural Biology of Bacterial Iron Uptake Systems显示文摘Clarke T C Tari L W Vogel H J 0,,:1
14Plant aromatic L-amino acid decarboxylases: evolution, biochemistry, regulation, and metabolic engineering applications 显示文摘Faeehini P J Huber Allanach K L Tari L W 2000Phytochemistry2000,54,2:1
15Discovering drug- drug interactions: a text-mining and reasoning approach based on properties of drug metabolism 显示文摘TARI L ANWAR S LIANG S 2010Bioinformat- ics2010,26,18:1
16Fuzzy c-means clustering with prior biological knowledge显示文摘Tari L Baral C Kim S 2009Journal of Biomedical Informatics2009,42,1:1
17The relationship between quality management practices and their effects on quality outcomes显示文摘TARI J J MOLINA J F CASTEJON J L 2007European Journal of Operational Research2007,183,:1
18Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism 显示文摘Tari L Anwar S Liang S 2010Bioinformaties2010,26,18:1
19Structural basis for the inhibition of Aurora A kinase by a novel class of high af?nity disubstituted pyrimidine inhibitors 显示文摘TARI L W HOFFMAN I D BENSEN D C 2007Bioorg Med Chem Lett2007,17,3:1
20Fuzzy C means clustering with prior biological knowledge显示文摘Tari L Chitta B Seungchan K 2009Journal of Biomedical Informatics2009,42,:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费